Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

Fig. 2

Associations of ctDNA-adjusted bTMB in patients receiving atezolizumab vs. docetaxel treatment. Comparison of (A) durable clinical benefit (DCB) and (B) objective response rate (ORR) between patients with high and low ctDNA-adjusted bTMB in atezolizumab arm and docetaxel arm. Predictive capacity for (C) OS and (D) PFS is stratified by treatment with atezolizumab vs. docetaxel in patients with low and high ctDNA-adjusted bTMB in OAK and POPLAR cohort

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us